Actions
Milan
,
Italy
28 September - 2 October 2026
62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026)
Interview with Professor Tina Vilsbøll, Senior Medical Officer, Novo Nordisk A/S
Medical Commentary: Draft ADA/EASD Consensus Report 2026
In this interview, Professor Tina Vilsbøll shares her clinical perspective on the draft ADA/EASD Consensus Report 2026, following its release for public comment at ADA 2026 and ahead of the final report at EASD 2026. She reflects on the growing role of GLP-1–based therapy, the shift from glucose-focused care to a broader view of the whole patient, and the increasing focus on comorbidities including cardiovascular, kidney and liver disease.
Presentation schedule and materials
Monday, 28 September 2026
09:00
- 16:30
CEST
Symposium
Advancing person-centred care across the cardiometabolic spectrum through scientific innovation
MATERIALS AVAILABLE
Coming soon
Tuesday, 29 September 2026
16:15
- 16:45
CEST
Symposium
Essence of MASH management: practical strategies to improve patient outcomes in diabetes clinics
Alice Cheng
;
Philip Newsome
MATERIALS AVAILABLE
Coming soon
18:00
- 19:30
CEST
Symposium
Semaglutide in obesity care: comprehensive evidence and emerging science
Jaime Almandoz
;
Sean Wharton
;
Barbara McGowan
;
Liana Billings
MATERIALS AVAILABLE
Coming soon
Wednesday, 30 September 2026
17:45
- 19:15
CEST
Symposium
Advancing the amylin story: from scientific rationale to future cardiometabolic care
MATERIALS AVAILABLE
Coming soon
Thursday, 01 October 2026
12:15
- 12:45
CEST
Symposium
Let’s talk amylin: the next wave in metabolic and obesity care
W. Timothy Garvey
;
Akshay Jain
;
Liana Billings
MATERIALS AVAILABLE
Coming soon
18:45
- 20:15
CEST
Symposium
Changing the trajectory of chronic metabolic disease: the evolving role of GLP-1-based care
Alice Cheng
;
Kirsi Pietiläinen
;
Eric Lawitz
;
Katherine Tuttle
MATERIALS AVAILABLE
Coming soon
Actions
Keywords